Bioorganic and Medicinal Chemistry Letters p. 4080 - 4083 (2012)
Update date:2022-08-03
Topics:
Subasinghe, Nalin L.
Wall, Mark J.
Winters, Michael P.
Qin, Ning
Lubin, Mary Lou
Finley, Michael F.A.
Brandt, Michael R.
Neeper, Michael P.
Schneider, Craig R.
Colburn, Raymond W.
Flores, Christopher M.
Sui, Zhihua
Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. However, even though intrathecally delivered synthetic ω-conotoxin MVIIA from Conus magnus (ziconotide [Prialt]) has been approved for the treatment of chronic pain in humans, its mode of delivery and narrow therapeutic window have limited its usefulness. Therefore, the identification of orally active, small-molecule N-type calcium channel blockers would represent a significant advancement in the treatment of chronic pain. A novel series of pyrazole-based N-type calcium channel blockers was identified by structural modification of a high-throughput screening hit and further optimized to improve potency and metabolic stability. In vivo efficacy in rat models of inflammatory and neuropathic pain was demonstrated by a representative compound from this series.
Tengzhou Runlong Fragrance Co., Ltd.
website:http://www.tzrunlong.com/
Contact:--
Address:No. 78, Fushan Road, Biomedical Industrial Park, Dawu Town, Tengzhou, Shandong, 277514 China
Contact:27-792-602929
Address:SIDNEY MUFAMADI STREET 009949 X44 0700 POLOKWANE,LIMPOPO
Nanjing Yuance Industry&Trade Co., Ltd.
website:http://www.njyuance.cn/
Contact:+86-25-85439097
Address:B1702, Aoti Bldg, No. 130, Aoti Avenue, Nanjing, China
Taizhou Shengxing Chempharm Co.,Ltd
Contact:+86-576-88516600
Address:Yantou Chemical Zone Jiaojiang Taizhou Zhejiang China
Contact:86-021-52418058
Address:8/F, Building 6, Guiping Road No.333, Shanghai, 200233, China
Doi:10.1039/c0cc04348f
(2011)Doi:10.1016/j.bmcl.2015.07.023
(2015)Doi:10.1016/0040-4039(91)85090-R
(1991)Doi:10.1021/ja00167a070
(1990)Doi:10.1016/j.bmcl.2010.11.010
(2011)Doi:10.1021/ja111540g
(2011)
